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Abstract
Introduction: The Department of Defense (DoD) and the Department of Veterans Affairs (VA) provide comprehensive HIV
treatment and care to their beneficiaries with open access and few costs to the patient. Individuals who receive HIV care in
the VA have higher rates of substance abuse, homelessness and unemployment than individuals who receive HIV care in the
DoD. A comparison between individuals receiving HIV treatment and care from the DoD and the VA provides an
opportunity to explore the impact of individual-level characteristics on clinical outcomes within two healthcare systems that
are optimized for clinic retention and medication adherence.
Methods: Data were collected on 1065 patients from the HIV Atlanta VA Cohort Study (HAVACS) and 1199 patients from the
US Military HIV Natural History Study (NHS). Patients were eligible if they had an HIV diagnosis and began HAART between
January 1, 1996 and June 30, 2010. The analysis examined the survival from HAART initiation to all-cause mortality or an
AIDS event.
Results: Although there was substantial between-cohort heterogeneity and the 12-year survival of participants in NHS was
significantly higher than in HAVACS in crude analyses, this survival disparity was reduced from 21.5% to 1.6% (mortality
only) and 26.8% to 4.1% (combined mortality or AIDS) when controlling for clinical and demographic variables.
Conclusion: We assessed the clinical outcomes for individuals with HIV from two very similar government-sponsored
healthcare systems that reduced or eliminated many barriers associated with accessing treatment and care. After controlling
for clinical and demographic variables, both 12-year survival and AIDS-free survival rates were similar for the two study
cohorts who have open access to care and medication despite dramatic differences in socioeconomic and behavioral
characteristics.
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Introduction
In the HAART era, individuals with HIV are living longer after
their HIV diagnoses [1]. When compared to similar populations
diagnosed with HIV prior to HAART availability, individuals with
HIV in the modern HAART era suffer a range of health
challenges that are associated with aging and therapy, including
comorbid illnesses [2]. The complex nature of the treatment for
these diseases can be a significant barrier for patients attempting to
remain adherent with care. The same risk factors associated with
HIV transmission such as poverty, discrimination, and inadequate
education, persist or become exacerbated after HIV infection and
can also serve as major barriers to healthcare retention [3,4].
Other barriers are inherent to the healthcare system and payer
source, such as enrollment applications, pre-existing conditions
and copayments. When compounded with the barriers that are
specific to the individual, these impediments can result in
treatment discontinuation and adverse clinical outcomes which
can ultimately impact on the overall cost-effectiveness of HIV
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treatment and care for a particular program. Thus, complex and
chronic diseases require an integration of multiple services and
providers and as few socioeconomic obstacles as possible in order
to simultaneously improve outcomes and increase efficiency [5,6].
It has not been clearly demonstrated how a healthcare system
should be organized to address these challenges within a defined
amount of resources.
Providing integrated, multi-disciplinary healthcare for individ-
uals with HIV has been a significant challenge for most clinicians
functioning within the constraints of a contemporary practice. In
addition to primary care services, such a system usually requires a
broad range of medical services, including a full-service pharmacy,
a laboratory, comprehensive prevention and education programs,
mental health services, and physical therapy. Both the Department
of Defense (DoD) and the Department of Veterans Affairs (VA)
provide comprehensive HIV treatment and care to their
beneficiaries with little or no out-of-pocket costs to the patient
and with open access.
In preparation for subsequent cost effectiveness comparisons,
this study aimed to compare clinical outcomes associated with
HIV treatment and care for patients from both the HIV Atlanta
VA Cohort Study (HAVACS) and the US Military HIV Natural
History Study (NHS) cohorts. The Department of Defense (DoD)
and the Department of Veterans Affairs (VA) provide compre-
hensive HIV treatment and care to their beneficiaries with open
access and few costs to the patient. This comparison between
individuals receiving HIV treatment and care from the DoD and
the VA provided an opportunity to explore the impact of
individual-level characteristics on clinical outcomes within two
healthcare systems that are optimized for clinic retention and
medication adherence. Furthermore, we sought to characterize,
when possible, the relative contribution of these individual-level
factors to clinical outcomes when access to care is not a
confounding issue.
Methods
Study Participants
Data were collected from the two cohorts: the HAVACS and
the NHS. The NHS has enrolled over 5000 beneficiaries into a
prospective, multicenter observational study of active duty military
personnel and other military beneficiaries living with HIV since
1986. The NHS cohort characteristics have been previously
described [7]. As a result of routine HIV screening in the military,
NHS cohort members are diagnosed early and the majority has
estimated dates of seroconversion. The HAVACS includes all
veterans living with HIV who have received treatment and care at
the Atlanta VA Medical Center since 1982 (n.3800). The cohort
characteristics of HAVACS have been previously described [8].
Data have been prospectively collected for both cohorts and are
used for clinical care and research purposes. The NHS cohort has
been approved by the Institutional Review Board (IRB) centrally
(Uniformed Services University of the Health Sciences, Bethesda,
MD) and at each participating center (Walter Reed National
Military Medical Center, Bethesda, MD; Naval Medical Center,
Portsmouth, VA; San Antonio Military Medical Center, TX;
Naval Medical Center, San Diego, CA; and Tripler Army Medical
Center, Honolulu, HI). Written consent was obtained from each
patient. The HAVACS cohort has been approved by Emory
University’s IRB and the Atlanta VA Medical Center Research
and Development Committee. The HAVACS cohort does not
require patients’ written consent as it has an IRB-approved
HIPAA waiver.
Patients in both cohorts were eligible for inclusion in this
analysis if they had an HIV diagnosis and began HAART between
January 1, 1996 and June 30, 2010. A total of 1199 NHS patients
and 1065 HAVACS patients were followed from their recorded
HAART initiation date through all-cause mortality, an AIDS-
defining event, or the date of last data entry for these analyses.
Variable Definitions
For the survival analyses, an AIDS-defining event utilized the
1993 CDC definition of AIDS; however, given the amount of
HAVACS patients who had CD4 counts below 200 cells/mm3 at
study enrollment, CD4,200 was not included in this definition
but was analyzed separately. A HAART regimen was defined as
the use of three or more antiretroviral medications, one of which
has to be a protease inhibitor (PI), a non-nucleoside reverse
transcriptase inhibitor (NNRTI), an integrase inhibitor, or an
entry inhibitor. A participant’s HAART initiation date was the
date of the first HAART regimen that lasted greater than one
month. This regimen was recorded as the participant’s initial
HAART regimen, regardless of any subsequent changes in drugs,
thus utilizing an intention to treat format for this variable.
Information regarding the participant’s age at HAART initiation,
sex, race, year of HIV diagnosis, viral load and CD4 count at
HAART initiation (within three months of HAART start date),
history of chronic hepatitis B and C co-infection, and previous
ARV use (mono or dual NRTI) were also analyzed.
The distribution of HIV-1 viral loads was determined by the
values available in each three month period from 1996 through
2010. These were then presented as values ,50, 51–400, 400 to
10,000, and greater than 10,000 copies/ml (Figure 1).
Statistical Analysis
Potential variables were selected based on previously published
findings regarding influences on survival of patients living with
HIV in the presence of HAART [9]. Two-sided Wilcoxon rank
sum and chi-square (x2) tests were used to compare the selected
variables across the two cohorts. The variables were subsequently
screened using bivariate analyses and were dropped from further
inclusion in multivariate models if their crude association’s p-value
with the outcomes were greater than 0.5. Only one variable, year
of HIV diagnosis, did not meet the threshold for inclusion into the
multivariate analyses. All interactions were considered and
dropped using a backwards elimination approach with a likelihood
ratio test for significance. All remaining variables were assessed for
collinearity. Variables that remained after these procedures were
utilized throughout all analyses for comparison between models.
The proportional hazards (PH) assumptions were gauged for each
variable utilizing a consensus of three different approaches:
graphical, goodness of fit, and extended Cox modeling. All
variables of interest satisfied the PH assumption. The Akaike
Information Criterion (AIC) was also used to determine if a
credible difference between a full model using all variables of
interest and a more parsimonious model using any combination of
variables might exist [10]. The full model’s AIC value
(AIC= 1778.4) was similar to the parsimonious model’s AIC
value (AIC= 1773.6); thus, the full model was chosen and these
results were reported.
Two separate outcomes were assessed for each cohort: time to
all-cause mortality and time to all-cause mortality or an AIDS-
defining event (excluding CD4,200), whichever occurred first.
For both, follow-up began at time of HAART initiation. Cox
proportional hazards models were fitted to investigate mortality
and AIDS rates by cohort. Survival curves, both unadjusted and
adjusted, were estimated using the corrected group prognosis
HIV Outcomes in the US Military and Veterans
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method [11]. Analyses were conducted with SAS 9.2 (SAS, Cary,
NC, USA).
Results
Baseline and Demographic Characteristics
Table 1 shows the substantial between-cohort heterogeneity.
HAVACS participants were older at HAART initiation with a
median age of 42 years compared to 31 years in NHS (p,0.0001).
Although both cohorts are predominantly male (,5% of the total
study population was female), the NHS cohort did have
significantly more females than did HAVACS (p,0.0001). Eighty
percent of HAVACS patients were African-American/Black while
the NHS cohort was more evenly divided between African-
American/Black and European-American/White race (42.6%
and 41.0%, respectively) (p,0.0001). Given the lack of other
races represented in HAVACS, no other race was specifically
analyzed although 16.4% of the NHS was neither African-
American/Black nor European- American/White.
Clinical, Virologic and Immunologic Characteristics
HAVACS participants were more likely to have had an AIDS-
defining event (whether including or excluding CD4,200) prior to
HAART initiation and were more likely to be hepatitis C and
hepatitis B co-infected at HAART initiation (all p,0.0001).
HAVACS patients had a lower CD4 cell count at HAART
initiation with a median count of 188.0 cells/mm3 (IQR 49.5–
296.5) compared to 341.0 cells/mm3 (IQR 251.0–461.0) at
HAART initiation for patients in the NHS (p,0.0001). The
distribution of viral load measurements at HAART initiation were
less striking between the cohorts but were still significantly
different with HAVACS participants having higher viral load
levels (median 4.8 log copies/mL; IQR 4.2–5.4) compared to
NHS participants (mean 4.6 log copies/mL; IQR 4.0–5.0)
(p,0.0001).
Antiretroviral Usage
Although the HAVACS participants were diagnosed with HIV
in an earlier calendar year than those in the NHS, there was no
statistically significant difference in time from HIV diagnosis to
Figure 1. Quarterly HIV viral load distributions within each HAART-initiating cohort from January 1, 1996 to June 30, 2010.
doi:10.1371/journal.pone.0062273.g001
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HAART initiation (approximately five months), although there
was substantial variability in this time. Patients in HAVACS were
more likely to have used mono or dual ARV therapy before
HAART (19.7% vs. 16.6%, p=0.0245); however, based on year of
HIV diagnosis and years included in this analysis, this was not a
common event. Both cohorts had an average time to HAART
initiation from nadir CD4 of one month or less, yet the difference
between these cohorts was still statistically significant (p,0.0001).
Although the type of initial HAART regimen was statistically
significantly different between the two cohorts, both groups were
most likely to initiate HAART with a NNRTI-containing regimen
Table 1. Distributions of variables between NHS and HAVACS.
Variable Cohort
NHS (n=1199) HAVACS (n=1065) Pa
Demographics
Age at HAART initiation, yearsb 31.0 (25.0–37.0) 42.0 (35.0–51.0) ,0.0001
Female 6.8% (82) 2.5% (27) ,0.0001
Race
African-American/Black 42.6% (511) 78.8% (838) ,0.0001
European-American/White 41.0% (491) 19.8% (211)
Other 16.4% (197) 1.4% (15)
Medical history (prior to HAART initiation)
Year of HIV diagnosis 200164.0 200063.8 0.0003
HIV diagnosis to HAART initiation, monthsb 4.7 (1.6–16.9) 5.0 (1.2–23.3) 0.6774
Viral load at HAART initiation, log copies/mLb 4.6 (4.0–5.0) 4.8 (4.2–5.4) ,0.0001
,2.60 5.9% (67) 6.6% (44) 0.0138
2.60–4.00 17.6% (201) 12.5% (83)
.4.00 76.5% (872) 80.9% (539)
Nadir CD4+ to HAART initiation, monthsb 0.9 (0.2–3.0) 1.0 (0.8–3.9) ,0.0001
CD4+ at HAART initiation, cells/mm3 b 341.0 (251.0–461.0) 188.0 (49.5–296.5) ,0.0001
,200 14.1% (159) 53.0% (443) ,0.0001
200–349 37.4% (420) 28.3% (237)
350+ 48.5% (545) 18.7% (156)
Previous AIDS-defining eventc
AIDS-defining event (inclusive of CD4) 16.6% (199) 54.8% (584) ,0.0001
AIDS-defining event (exclusive of CD4) 3.4% (41) 20.2% (215) ,0.0001
CD4,200/14% 15.1% (181) 39.3% (419) ,0.0001
Chronic hepatitis B co-infection 1.5% (18) 5.5% (59) ,0.0001
Hepatitis C co-infection 2.8% (33) 12.7% (135) ,0.0001
Previous ARV use (mono or dual therapy) 16.1% (193) 19.7% (210) 0.0245
Initial HAART regimen
Unboosted PI 27.7% (333) 28.4% (302) ,0.0001
Boosted PI 13.0% (154) 16.0% (170)
NNRTI 51.3% (610) 52.6% (560)
PI/NNRTI/NRTI 2.0% (24) 0.3% (3)
3NRTI 6.0% (71) 2.8% (30)
Outcomes
Died 3.2% (38) 17.1% (182) ,0.0001
AIDS after HAART initiationc
AIDS-defining event (inclusive of CD4) 6.4% (77) 24.0% (256) ,0.0001
AIDS-defining event (exclusive of CD4) 2.6% (31) 13.2% (140) ,0.0001
CD4,200/14% 4.4% (53) 12.9% (137) ,0.0001
NHS-US Military HIV Natural History Study; HAVACS-HIV Atlanta VA Cohort Study; HAART-Highly Active Antiretroviral Therapy; IQR-interquartile range; PI-Protease
Inhibitor; NNRTI-Non-Nucleoside Reverse Transcriptase Inhibitor; NRTI-Nucleoside Reverse Transcriptase Inhibitor.
aTested for significance with two-sided Wilcoxon rank-sum and chi-square (x2) tests.
bShowed in median units (IQR).
cAIDS-defining event utilizes the 1993 CDC definition.
doi:10.1371/journal.pone.0062273.t001
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and less likely to have initiated HAART with either a regimen
containing a PI or three NRTIs.
Outcomes
During 185,356 person-months of follow-up, 220 (9.7%)
patients died. The majority of these patients were from HAVACS
(n = 182, 17.1%) compared with the NHS (n= 38, 3.2%)
(p,0.0001). HAVACS patients were also more likely to have an
AIDS-defining event after HAART initiation; 13.2% of HAVACS
patients compared to 2.6% of NHS patients (p,0.0001). When
CD4,200 cells/mm3 was included, 24.0% of HAVACS patients
had an AIDS-defining event compared to 6.4% of NHS
(p,0.0001).
The distribution of HIV-1 viral loads by quarter is shown in
Figure 1. Before 2005, some differences may have been due to
technical issues with processing specimens [12] in HAVACS. After
2005, the distribution of values is very similar, showing that more
than 70% of the patients in both cohorts had undetectable viral
loads below 50 copies/mL by the end of the study period.
Table 2 displays the crude hazard ratios (cHR) and adjusted
hazard ratios (aHR) for Cox proportional hazards modeling for
both outcomes of interest. In all models, the survival of
participants in the NHS cohort was significantly greater than in
the HAVACS. After controlling for age, sex, race, CD4 and VL at
HAART initiation, prior AIDS, Hepatitis B and C, prior ARV
usage and regimen, the 12-year survival rates between the cohorts
decreased from a 21.5% crude difference (NHS–91.5%; HA-
VACS–70.0%) to a 1.6% adjusted difference (NHS–98.7%;
HAVACS–97.1%) (Figure 2). Similarly, the difference in the 12-
year survival rates to combined mortality/AIDS events between
the cohorts decreased from a 26.8% crude difference (NHS–
87.8%; HAVACS–61.0%) to a 4.1% adjusted difference (NHS–
95.8%; HAVACS–91.7%). Patients in the NHS were 57% less
likely to die during follow-up compared to patients in HAVACS
Figure 2. a. Unadjusted and adjusted survival curves from HAART initiation to death by cohort. b. Unadjusted and adjusted survival curves from
HAART initiation to death or AIDS (excl. CD4,200) by cohort.
doi:10.1371/journal.pone.0062273.g002
HIV Outcomes in the US Military and Veterans
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(aHR 0.43, 95% confidence interval (CI) 0.27, 0.70) and were
51% less likely to have reached the composite outcome of death or
AIDS-defining event (aHR 0.49, 95% CI 0.34, 0.71) compared to
patients in HAVACS.
Discussion
In this analysis, we assessed the clinical outcomes for individuals
with HIV from two very similar government-sponsored healthcare
systems that were designed to reduce or eliminate many of the
barriers associated with accessing treatment and care. Patients
with DoD or VA health benefits do not face interruptions in care
or eligibility exclusions due to interstate migration, changes in
employment or income-level, or pre-existing medical conditions.
With few exceptions, medications and care require little or no out-
of-pocket fees or copayments for eligible individuals. With these
significant barriers removed, even individuals who are homeless,
unemployed and suffer from multiple comorbidities and substance
abuse disorders can receive high quality, uninterrupted treatment
and care. Both populations also share a common origin of active
duty service which provides a unique opportunity to examine the
impact of changing socioeconomic and behavioral structures in
light of similar occupational skills, educational backgrounds and
training experiences. However from the data presented, it is clear
that the VA population studied differed substantially in nearly all
clinical characteristics measured compared to the DoD population
studied. The VA population has significantly greater comorbidities
such as hepatitis C (also a marker for intravenous drug use, which
is nearly absent in the NHS [13]) and hepatitis B co-infection as
well as more AIDS-defining events. They are also older and have
lower CD4 counts on average than those in the DoD in part
reflecting a later adoption of routine HIV screening. By law,
routine opt-out testing could not be performed in the VA until
August 2009. This is perhaps the most important distinction
between these two populations. It is likely that the longer time
from HIV seroconversion to HIV diagnosis and subsequent
HAART initiation for patients in the VA accounts for most of the
clinical differences observed between these two cohorts.
Similarly, previous reports have shown that these two popula-
tions also differ substantially with regards to socioeconomic and
behavioral characteristics as well as non-AIDS-related comorbid-
ities such as diabetes mellitus (DM), cardiovascular disease (CVD),
and pulmonary disease. Though these data were not available on
individual patients and thus could not be controlled for in the
analyses, the possible impact can be inferred by aggregate
Table 2. Crude and adjusted predictors of time to development of outcomes after initiating HAART using Cox proportional
hazards modeling.
Variable Death (n=1727) Death or AIDS-defining event
a (n=1726)
cHR aHR cHR aHR
Cohort, NHS vs. HAVACS 0.26 (0.18, 0.36) 0.43 (0.27, 0.70) 0.27 (0.20, 0.35) 0.49 (0.34, 0.71)
Demographics
Age at HAART initiation 1.07 (1.06, 1.08) 1.06 (1.04, 1.08) 1.06 (1.05, 1.07) 1.04 (1.03, 1.05)
Sex, female vs. male 2.31 (0.95, 5.61) 2.64 (0.64, 10.80) 2.54 (1.20, 5.36) 2.11 (0.78, 5.73)
Race, AA vs. other 1.63 (1.21, 2.20) 1.20 (0.80, 1.79) 1.66 (1.31, 2.12) 1.08 (0.78, 1.50)
Medical history (prior to HAART initiation)
HIV diagnosis to HAART initiation, years 1.07 (0.98, 1.16) 0.97 (0.87, 1.07) 1.06 (1.00, 1.13) 1.00 (0.92, 1.07)
Viral load at HAART initiation, log copies/mL
,2.60 0.52 (0.23, 1.17) 0.46 (0.19, 1.15) 0.41 (0.19, 0.86) 0.37 (0.16, 0.83)
2.60–4.00 1.05 (0.69, 1.60) 1.46 (0.91, 2.33) 0.86 (0.59, 1.26) 1.22 (0.81, 1.85)
.4.00 1.00 1.00 1.00 1.00
CD4+ at HAART initiation, cells/mm3
,200 3.45 (2.36, 5.04) 1.28 (0.79, 2.07) 4.03 (2.94, 5.52) 1.62 (1.08, 2.43)
200–349 1.08 (0.66, 1.76) 0.60 (0.34, 1.03) 1.24 (0.83, 1.83) 0.85 (0.55, 1.32)
350+ 1.00 1.00 1.00 1.00
Previous AIDS-defining eventa 2.24 (1.63, 3.06) 0.95 (0.62, 1.43) 2.70 (2.10, 3.47) 1.27 (0.90, 1.78)
Chronic hepatitis B co-infection 2.51 (1.53, 4.12) 1.89 (1.10, 3.25) 1.94 (1.23, 3.05) 1.39 (0.84, 2.29)
Hepatitis C co-infection 3.66 (2.66, 5.03) 1.60 (1.08, 2.38) 2.76 (2.08, 3.66) 1.40 (0.99, 1.98)
Previous ARV use (mono or dual therapy) 1.34 (0.99, 1.82) 1.40 (0.95, 2.07) 1.40 (1.09, 1.80) 1.39 (1.00, 1.91)
Initial HAART regimen
NNRTI 1.00 1.00 1.00 1.00
Boosted PI 1.47 (0.98, 2.22) 1.78 (1.10, 2.86) 1.83 (1.35, 2.50) 2.10 (1.44, 3.05)
Unboosted PI 1.04 (0.76, 1.41) 1.28 (0.86, 1.90) 1.07 (0.83, 1.38) 1.32 (0.95, 1.83)
Other 0.34 (0.14, 0.83) 0.72 (0.25, 2.01) 0.32 (0.15, 0.69) 0.45 (0.17, 1.27)
Note: Bold hazard ratios (HR) and 95% confidence intervals (CI) are significant at the p,0.05 level.
HAART-Highly Active Antiretroviral Therapy; NHS-US Military HIV Natural History Study; HAVACS-HIV Atlanta VA Cohort Study; AA-African -American/Black; PI-Protease
Inhibitor; NNRTI-Non-Nucleoside Reverse Transcriptase Inhibitor.
a1993 definition, exclusive of CD4,200.
doi:10.1371/journal.pone.0062273.t002
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numbers illustrating the differences between these two groups.
National data from the VA Cohort Study (VACS) show rates of
unemployment to be 11–13%, 12% of veterans are currently
homeless and 32% have been homeless at some point, 30% suffer
from depression, and substance abuse disorders range from 5–63%
in this population [14]. In contrast, the DoD housing, employ-
ment/income, depression and substance abuse rates from the 2008
DoD Health Related Behaviors survey were respectively 6.2%
(difficulty with housing), 8.6% (difficulty with money), 2.3% (any
substance abuse excluding prescription drugs), and 21% (need for
depression evaluation in past 7 days) [13]. The impact of
differences in non-AIDS related comorbidities can also be
extrapolated from previously published data. Data from VACS
show rates of 8% for DM and 6% for CVD [15], while data for
military members on active duty show rates of 4.5% for DM and
5.9% for CVD [16]. Though the data for active duty includes
HIV+ and HIV- military members and therefore is not completely
comparable, these are the best data available.
Despite large clinical and social differences, the study period
survival rates for mortality and combined mortality/AIDS events
were dramatically mitigated (19.9% and 22.7% reduction in
between-cohort differences, respectively) when adjusting for
important clinical and demographic variables. The adjusted
survival differences were only 1.6% and 4.1% for each respective
endpoint after controlling for these variables. Though both systems
provide free or low-cost access to health care for eligible patients
with HIV, only the DoD routinely screens for HIV and thus, these
patients were generally diagnosed at an earlier stage in their HIV
disease. Although patients in both the NHS and HAVACS were
likely to be started on HAART within one month of their HIV
diagnosis, 48.5% of the NHS patients had a CD4.350 at time of
HAART initiation compared to 18.7% of HAVACS patients
implying diagnosis at an earlier stage of disease for NHS patients.
The impact of early diagnosis cannot be underestimated. Patients
who started HAART with a CD4,200 cells/mL were 62.1%
more likely to die or have an AIDS-defining event during follow-
up (95% CI 1.08, 2.43) when compared to those who started with
a CD4.500. Given the DHHS guidelines to start HAART at a
CD4.500 cells/mL [17], this is not a surprising finding and
continues to stress the need for earlier detection, even in health
care systems with no barriers to testing or treatment. It is
conceivable that healthcare systems which invest more in both
HIV screening and early treatment can ultimately show a cost-
savings at the institution and societal levels by achieving stable and
superior clinical effectiveness. These upfront costs would involve
early and aggressive identification of individuals with HIV
infection followed by active participation in a comprehensive,
integrated treatment and care program (including disease preven-
tion and wellness education) which has reduced or eliminated
many of the system-associated barriers to care [5,6]. Subsequently,
patients would be less likely to experience adverse events related to
HIV infection, medications or comorbidities and would require
less hospital admissions and salvage treatment that, in turn, would
improve quality of life, reduce overall costs and increase worker
productivity [18–21]. Sustained virologic suppression will also
result in fewer secondary HIV transmission events which in turn
will result in additional individual, institutional and societal
benefits [22].
Our findings are limited by the inability to specifically adjust for
socioeconomic and behavioral variables and non-AIDS defining
comorbidities which most certainly have an impact on clinical
outcomes. Additionally, because the HAVACS patients have a
lower CD4 at HAART initiation, this may add some survivor bias
to the analysis. Furthermore, since data for a fee-for-care group
are unavailable, it is difficult to speculate how these open access to
care and medication systems would compare with regard to
clinical outcomes.
Conclusions
We assessed the clinical outcomes for individuals with HIV from
two very similar government-sponsored healthcare systems that
reduced or eliminated many barriers associated with accessing
treatment and care. The combined total mortality rate was less
than 10% for those diagnosed with HIV and initiated HAART
since 1996. The NHS patients were younger and started HAART
sooner during HIV infection with a higher CD4 cell count and
experienced less mortality than HAVACS patients. Despite these
substantial differences in baseline characteristics and large
differences in crude mortality rates, after controlling for important
clinical and demographic variables, both 12-year survival and
AIDS-free survival rates were similar between the two study
cohorts who have open access to care and medication. These
similarities existed despite dramatic differences in socioeconomic
and behavioral characteristics. The remaining significant differ-
ence in survival may be due to uncontrolled social issues, and
additional non-AIDS comorbidities (such as DM or CVD). Future
studies should investigate comparisons of clinical outcomes in fee-
for-care systems and factors including drug abuse, mental health
issues, and socioeconomic differences, as well as impact of early
HIV screening. Our data suggest that early screening, with
subsequent higher CD4 at diagnosis, will result in improved
outcomes.
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